Compare Albertsons Companies Inc (ACI) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Adaptive Biotechnologies Corp — how do they compare? Albertsons Companies Inc trades at $12.25 (market cap $5.95B), while Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B). The key difference: Albertsons Companies Inc is the larger of the two by market cap, and Albertsons Companies Inc pays a 5.55% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ACI | ADPT | |
|---|---|---|
Market Cap | $5.95B | $4.04B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $25.45 |
52-Week Low | $11.03 | $12.30 |
Enterprise Value | $21.35B | $4.10B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $12.13, up 1.0% on the day, but remains near multi-year lows after a sharp 22% drop following Q2 2026 earnings miss and lowered guidance. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $80.39B in 2025, but net income margin compressed to 0.08%, reflecting margin pressure. Recent news highlights CEO and CFO stock purchases, AI initiatives like the Safeway ChatGPT plugin, and ongoing shareholder litigation investigations.
The outlook is cautious; ACI presents a deep-value case with low P/S of 0.08, but execution risks and weak profitability trends pose challenges. Analyst consensus is mixed with a $13.20 price target. Key risks include competitive grocery margins, litigation overhangs, and macroeconomic headwinds affecting consumer spending.
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
